Capricor Therapeutics Faces FDA Rejection for Duchenne Treatment
By Editor • August 20, 2026 • 1 min read
Capricor Therapeutics is on the brink of an FDA rejection for its Duchenne muscular dystrophy cell therapy, deramiocel. In a last-ditch effort, the company has submitted results from an open-label extension of an unsuccessful Phase 3 trial.
However, experts view this move as merely a stalling tactic.
Source: www.statnews.com
#Capricor Therapeutics #clinical trial #deramiocel #Duchenne muscular dystrophy #FDA
